Which has higher earnings and valuation, MGX or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Metagenomi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Metagenomi $25.21M 1.37 -$87.87M -$2.49 N/A CytoMed Therapeutics $250K 41.17 -$3.10M N/A N/A

Does the media refer more to MGX or GDTC?

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Metagenomi. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.91 beat CytoMed Therapeutics' score of 0.47 indicating that Metagenomi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ATNM or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actinium Pharmaceuticals $35.09M 0.90 -$48.82M $0.36 2.78 CytoMed Therapeutics $250K 41.17 -$3.10M N/A N/A

Is ATNM or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% CytoMed Therapeutics N/A N/A N/A

Does the media favor ATNM or GDTC?

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Actinium Pharmaceuticals. CytoMed Therapeutics' average media sentiment score of 0.47 beat Actinium Pharmaceuticals' score of 0.37 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BCTX or GDTC?

CytoMed Therapeutics has a consensus price target of $4.16, suggesting a potential upside of 378.16%. Given CytoMed Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytoMed Therapeutics is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, BCTX or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Briacell Therap. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A CytoMed Therapeutics $250K 41.17 -$3.10M N/A N/A

Is BCTX or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% CytoMed Therapeutics N/A N/A N/A

Does the media refer more to BCTX or GDTC?

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.82 beat CytoMed Therapeutics' score of 0.47 indicating that Briacell Therap is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, EDSA or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Edesa Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edesa Biotech N/A N/A -$7.19M -$1.69 N/A CytoMed Therapeutics $250K 41.17 -$3.10M N/A N/A

Is EDSA or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% CytoMed Therapeutics N/A N/A N/A

Which has higher valuation and earnings, ALGS or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aligos Therapeutics $2.19M 15.70 -$24.19M -$7.30 N/A CytoMed Therapeutics $250K 41.17 -$3.10M N/A N/A

Does the media refer more to ALGS or GDTC?

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.59 beat CytoMed Therapeutics' score of 0.47 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CytoMed Therapeutics (GDTC) Competitors

$0.84 -0.03 (-3.68%)

As of 04:00 PM Eastern

Compare

GDTC vs. MGX, ATNM, BCTX, EDSA, and ALGS

Should you buy CytoMed Therapeutics stock or one of its competitors? CytoMed Therapeutics's main competitors and comparable companies include Metagenomi (MGX), Actinium Pharmaceuticals (ATNM), Briacell Therap (BCTX), Edesa Biotech (EDSA), and Aligos Therapeutics (ALGS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CytoMed Therapeutics compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Metagenomi currently has a consensus price target of $6.00, suggesting a potential upside of 554.09%. CytoMed Therapeutics has a consensus price target of $4.16, suggesting a potential upside of 378.16%. Given Metagenomi's stronger consensus rating and higher possible upside, equities research analysts clearly believe Metagenomi is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Metagenomi. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.91 beat CytoMed Therapeutics' score of 0.47 indicating that Metagenomi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.0% of CytoMed Therapeutics shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CytoMed Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. CytoMed Therapeutics' return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
CytoMed Therapeutics	N/A	N/A	N/A

CytoMed Therapeutics has lower revenue, but higher earnings than Metagenomi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.37	-$87.87M	-$2.49	N/A
CytoMed Therapeutics	$250K	41.17	-$3.10M	N/A	N/A

Metagenomi has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

Summary

Metagenomi beats CytoMed Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

CytoMed Therapeutics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
CytoMed Therapeutics	N/A	N/A	N/A

Actinium Pharmaceuticals has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market.

Actinium Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 400.25%. CytoMed Therapeutics has a consensus target price of $4.16, indicating a potential upside of 378.16%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Actinium Pharmaceuticals is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CytoMed Therapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.90	-$48.82M	$0.36	2.78
CytoMed Therapeutics	$250K	41.17	-$3.10M	N/A	N/A

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Actinium Pharmaceuticals. CytoMed Therapeutics' average media sentiment score of 0.47 beat Actinium Pharmaceuticals' score of 0.37 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Actinium Pharmaceuticals and CytoMed Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

CytoMed Therapeutics' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
CytoMed Therapeutics	N/A	N/A	N/A

Briacell Therap has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market.

CytoMed Therapeutics has a consensus price target of $4.16, suggesting a potential upside of 378.16%. Given CytoMed Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytoMed Therapeutics is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CytoMed Therapeutics has higher revenue and earnings than Briacell Therap.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
CytoMed Therapeutics	$250K	41.17	-$3.10M	N/A	N/A

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.82 beat CytoMed Therapeutics' score of 0.47 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

CytoMed Therapeutics beats Briacell Therap on 8 of the 12 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Edesa Biotech has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market.

In the previous week, CytoMed Therapeutics had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.79 beat CytoMed Therapeutics' score of 0.47 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Edesa Biotech	Very Positive
CytoMed Therapeutics	Neutral

CytoMed Therapeutics has higher revenue and earnings than Edesa Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
CytoMed Therapeutics	$250K	41.17	-$3.10M	N/A	N/A

Edesa Biotech currently has a consensus target price of $5.00, suggesting a potential upside of 75.44%. CytoMed Therapeutics has a consensus target price of $4.16, suggesting a potential upside of 378.16%. Given CytoMed Therapeutics' higher possible upside, analysts plainly believe CytoMed Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CytoMed Therapeutics' return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
CytoMed Therapeutics	N/A	N/A	N/A

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Edesa Biotech and CytoMed Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

CytoMed Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.70	-$24.19M	-$7.30	N/A
CytoMed Therapeutics	$250K	41.17	-$3.10M	N/A	N/A

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.59 beat CytoMed Therapeutics' score of 0.47 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aligos Therapeutics has a beta of 2.36, suggesting that its stock price is 136% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market.

CytoMed Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. CytoMed Therapeutics' return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
CytoMed Therapeutics	N/A	N/A	N/A

Aligos Therapeutics currently has a consensus target price of $38.50, indicating a potential upside of 598.73%. CytoMed Therapeutics has a consensus target price of $4.16, indicating a potential upside of 378.16%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aligos Therapeutics is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aligos Therapeutics beats CytoMed Therapeutics on 9 of the 15 factors compared between the two stocks.

Get CytoMed Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GDTC vs. The Competition

Export

Metric	CytoMed Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.91M	$3.90B	$7.28B	$12.92B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	N/A	12.49	275.28	25.28
Price / Sales	39.65	1,151.22	562.38	78.55
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.86	16.55	10.52	5.92
Net Income	-$3.10M	-$22.69M	$3.50B	$381.04M
7 Day Performance	-14.49%	-6.66%	-4.32%	-4.41%
1 Month Performance	-1.61%	-14.41%	-8.66%	-7.30%
1 Year Performance	-62.76%	5.91%	1.94%	-5.04%

CytoMed Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GDTC CytoMed Therapeutics	1.7968 of 5 stars	$0.84 -3.7%	$4.16 +396.4%	-54.9%	$9.91M	$250K	N/A	42	Short Interest Increase Gap Down
MGX Metagenomi	4.1217 of 5 stars	$1.00 +0.7%	$6.00 +500.0%	-67.8%	$37.78M	$13.56M	N/A	113	News Coverage Gap Down
ATNM Actinium Pharmaceuticals	2.3924 of 5 stars	$1.10 +1.9%	$5.00 +354.5%	-37.9%	$34.59M	$35.09M	N/A	25
BCTX Briacell Therap	0.5952 of 5 stars	$3.91 -0.3%	N/A	-67.1%	$34.02M	N/A	N/A	4	Positive News
EDSA Edesa Biotech	2.9436 of 5 stars	$3.51 -4.1%	$5.00 +42.5%	+12.2%	$33.84M	N/A	N/A	17	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GDTC) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. MGX, ATNM, BCTX, EDSA, and ALGS

How does CytoMed Therapeutics compare to Metagenomi?

Summary

How does CytoMed Therapeutics compare to Actinium Pharmaceuticals?

Summary

How does CytoMed Therapeutics compare to Briacell Therap?

Summary

How does CytoMed Therapeutics compare to Edesa Biotech?

Summary

How does CytoMed Therapeutics compare to Aligos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. MGX, ATNM, BCTX, EDSA, and ALGS

How does CytoMed Therapeutics compare to Metagenomi?

Do analysts recommend MGX or GDTC?

Does the media refer more to MGX or GDTC?

Do insiders and institutionals hold more shares of MGX or GDTC?

Is MGX or GDTC more profitable?

Which has higher earnings and valuation, MGX or GDTC?

Which has more risk and volatility, MGX or GDTC?

Summary

How does CytoMed Therapeutics compare to Actinium Pharmaceuticals?

Is ATNM or GDTC more profitable?

Which has more volatility & risk, ATNM or GDTC?

Do analysts prefer ATNM or GDTC?

Do institutionals & insiders believe in ATNM or GDTC?

Which has better earnings and valuation, ATNM or GDTC?

Does the media favor ATNM or GDTC?

Summary

How does CytoMed Therapeutics compare to Briacell Therap?

Is BCTX or GDTC more profitable?

Which has more risk & volatility, BCTX or GDTC?

Do analysts rate BCTX or GDTC?

Which has stronger valuation and earnings, BCTX or GDTC?

Does the media refer more to BCTX or GDTC?

Do institutionals & insiders have more ownership in BCTX or GDTC?

Summary

How does CytoMed Therapeutics compare to Edesa Biotech?

Which has more risk and volatility, EDSA or GDTC?

Does the media refer more to EDSA or GDTC?

Which has better earnings & valuation, EDSA or GDTC?

Do analysts rate EDSA or GDTC?

Is EDSA or GDTC more profitable?

Do institutionals and insiders have more ownership in EDSA or GDTC?

Summary

How does CytoMed Therapeutics compare to Aligos Therapeutics?

Which has higher valuation and earnings, ALGS or GDTC?

Does the media refer more to ALGS or GDTC?

Do institutionals and insiders believe in ALGS or GDTC?

Which has more risk and volatility, ALGS or GDTC?

Is ALGS or GDTC more profitable?

Do analysts rate ALGS or GDTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools